Corcept Therapeutics (CORT) Gross Profit: 2009-2025
Historic Gross Profit for Corcept Therapeutics (CORT) over the last 13 years, with Sep 2025 value amounting to $203.0 million.
- Corcept Therapeutics' Gross Profit rose 13.00% to $203.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $727.8 million, marking a year-over-year increase of 17.62%. This contributed to the annual value of $664.2 million for FY2024, which is 39.56% up from last year.
- Latest data reveals that Corcept Therapeutics reported Gross Profit of $203.0 million as of Q3 2025, which was up 6.31% from $191.0 million recorded in Q2 2025.
- In the past 5 years, Corcept Therapeutics' Gross Profit registered a high of $203.0 million during Q3 2025, and its lowest value of $78.2 million during Q1 2021.
- Over the past 3 years, Corcept Therapeutics' median Gross Profit value was $154.8 million (recorded in 2025), while the average stood at $153.5 million.
- In the last 5 years, Corcept Therapeutics' Gross Profit fell by 14.45% in 2021 and then soared by 47.33% in 2024.
- Quarterly analysis of 5 years shows Corcept Therapeutics' Gross Profit stood at $97.5 million in 2021, then grew by 4.21% to $101.6 million in 2022, then soared by 31.46% to $133.5 million in 2023, then soared by 34.00% to $178.9 million in 2024, then grew by 13.00% to $203.0 million in 2025.
- Its last three reported values are $203.0 million in Q3 2025, $191.0 million for Q2 2025, and $154.8 million during Q1 2025.